Clinical trials: Neuroendrocrine Tumors

Neuroendrocrine Tumors, Meningioma

Dosimetry Guided PRRT With 90Y-DOTATOC

• Withdrawn
• Age: 6 months to 90 years
• Phase 2
• Surgery or procedure

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.

Conditions

Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma

Trial name

NCT03013387

Testing

90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids

Sponsor

Sue O'Dorisio